Skip to main content
SpringerLink
Log in

Immune checkpoint inhibitor toxicites from FAERS and OoSRs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Reference

  • Raschi E, et al. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. Targeted Oncology : 29 Mar 2019. Available from: URL: http://doi.org/10.1007/s11523-019-00632-w

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Immune checkpoint inhibitor toxicites from FAERS and OoSRs. Reactions Weekly 1748, 8 (2019). https://doi.org/10.1007/s40278-019-59924-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-59924-z

Search

Navigation